Eloxx Pharmaceuticals, Inc. (ELOX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-90.5%

$1.22

vs $12.84 price

Levered DCF

$3.38

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-4.95

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-2.06×	-1.19×	-0.15×	-0.06×	-0.03×	-0.03×	-0.02×	-0.02×
P/B	-1.04×	-0.15×	-0.11×	-0.2×	0.08×	0.1×	0.03×	0.02×
P/S	0×	0.59×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-1.73×	-5.54×	-0.36×	0.12×	0.42×	0.4×	0.12×	1.02×
Gross margin	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	-38.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	-49.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	0.31×	0.11×	0.07×	0.87×	4.37×	2.63×	4.89×	6.45×
Debt / equity	-0.08×	-0.27×	-0.18×	-1.26×	0.6×	1.18×	0.44×	0×
Interest coverage	-6.14×	-2.16×	-15.02×	-17.66×	-33.64×	-20.89×	-31.28×	-6,710.14×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	50.3%	12.9%	75.5%	338.3%	-298.1%	-338.0%	-140.5%	-110.0%
Return on invested capital	59.0%	13.9%	92.8%	-1260.9%	-118.2%	-132.2%	-97.3%	-109.5%
Return on assets	-113.8%	-105.6%	-996.1%	-170.7%	-147.8%	-130.6%	-86.3%	-93.0%
Free cash flow yield	0.0%	-125.3%	-557.4%	-1471.7%	-2004.4%	-2805.3%	-4140.0%	-3893.6%
Earnings yield	-48.5%	-83.5%	-662.8%	-1663.3%	-3811.5%	-3443.8%	-5341.4%	-5813.5%
Enterprise value	$8.6M	$10.2M	$5.4M	-$3.9M	-$27.4M	-$11.7M	-$5.8M	-$47.8M
Net debt / EBITDA	0.77×	-3.49×	-0.19×	0.18×	0.45×	0.44×	0.14×	1.04×
Cash conversion cycle (days)	0	156	0	-1,586	-524	-307	-1,222	-1,262